Evaluation of recombinant sporozoite antigen SPAG‐1 as a vaccine candidate against Theileria annulata by the use of different delivery systems
Evaluation of recombinant sporozoite antigen SPAG‐1 as a vaccine candidate against Theileria annulata by the use of different delivery systems
复制标题
使用不同的递送系统评价重组子孢子抗原SPAG-1作为针对环泰勒虫的候选疫苗
DOI：
--
复制
发表时间：
1999
影响因子：
3.3
通讯作者：
R. Hall
中科院分区：
文献类型：
--
作者：
N. Boulter;D. Brown;G. Wilkie;S. Williamson;E. Kirvar;P. Knight;E. Glass;J. Campbell;S. Morzaria;V. Nene;A. Musoke;C. d'Oliveira;Marc;F. Jongejan;R. Hall
摘要 环状泰勒虫 (SPAG-1) 的主要子孢子表面抗原是亚单位疫苗的候选者。在本文中，我们总结了使用在不同系统中表达并在不同佐剂中呈现的重组SPAG-1的4个疫苗接种实验的结果。该抗原以 C 端 108 个氨基酸肽（称为 SR1）的形式呈现，表达为 β-半乳糖苷酶和乙型肝炎核心抗原融合体，或者以全长形式表达为带有 N 端 His6 标签的 GST 融合体。我们使用了不同的佐剂，即弗氏佐剂、皂苷、ISCOM 和 SmithKline Beecham 提供的专有佐剂（我们称之为 SKBA）。数据表明，SPAG-1 可以引起部分保护，因此适合包含在最终的多组分亚单位疫苗中。
Summary The major sporozoite surface antigen of Theileria annulata (SPAG‐1) is a candidate for inclusion in a subunit vaccine. In this paper we summarize the results of 4 vaccination experiments using recombinant SPAG‐1 expressed in different systems and presented in different adjuvants. The antigen has been presented as either a C terminal 108 amino acid peptide (called SR1) expressed as both β‐galactosidase and hepatitis B core antigen fusions or as a full‐length form expressed as a GST fusion with an N terminal His6 tag. We used different adjuvants, namely Freund's, saponin, ISCOMs and a proprietary adjuvant supplied by SmithKline Beecham, which we call SKBA. The data point to the conclusion that SPAG‐1 can elicit partial protection and is therefore suitable for inclusion in an eventual multicomponent subunit vaccine.